Adage Capital Partners Gp, L.L.C. Trevi Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 440,000 shares of TRVI stock, worth $2.68 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
440,000
Previous 2,500,000
82.4%
Holding current value
$2.68 Million
Previous $10.7 Million
74.02%
% of portfolio
0.01%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
142Shares Held
85.3MCall Options Held
1.5MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$69.2 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$62.5 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$27.6 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$23.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$21.2 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $355M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...